biotin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	373	58-85-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: biotin coenzyme R D-Biotin	A water-soluble, enzyme co-factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk. Molecular weight: 244.31 Formula: C10H16N2O3S CLOGP: -0.08 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 78.43 ALOGS: -2.30 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

biotin
coenzyme R
D-Biotin

A water-soluble, enzyme co-factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk.

Molecular weight: 244.31
Formula: C10H16N2O3S
CLOGP: -0.08
LIPINSKI: 0
HAC: 5
HDO: 3
TPSA: 78.43
ALOGS: -2.30
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
EoM (Fraction excreted unchanged in urine)	43 %	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.22 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.01 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Showing 1 to 5 of 5 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Feb. 20, 1953	FDA	HOSPIRA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Fatigue	103.01	12.12	801	32282	887227	62568712
Toxicity to various agents	86.22	12.12	13	33070	247237	63208702
Synovitis	84.09	12.12	3	33080	186915	63269024
Pleural thickening	83.07	12.12	37	33046	2846	63453093
Blood magnesium increased	81.21	12.12	37	33046	3001	63452938
Presbyacusis	80.09	12.12	36	33047	2829	63453110
Product dose omission issue	77.39	12.12	283	32800	234030	63221909
Pleural fibrosis	76.50	12.12	37	33046	3435	63452504
Contraindicated product administered	72.41	12.12	13	33070	217635	63238304
COVID-19	71.35	12.12	172	32911	112931	63343008

Showing 1 to 10 of 125 entries

Previous1 2 3 4 5…13Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Fractional exhaled nitric oxide increased	202.41	23.51	44	5253	1038	34950596
Plantar fasciitis	163.24	23.51	42	5255	2074	34949560
Sensation of foreign body	161.10	23.51	44	5253	2739	34948895
Myoglobin blood increased	157.49	23.51	44	5253	2979	34948655
Brain natriuretic peptide increased	130.30	23.51	44	5253	5615	34946019
Secretion discharge	124.58	23.51	43	5254	5862	34945772
Appendicolith	101.85	23.51	41	5256	8560	34943074
Obstructive airways disorder	93.39	23.51	46	5251	15448	34936186
Exostosis	90.42	23.51	32	5265	4691	34946943
Dysphonia	86.10	23.51	50	5247	23333	34928301

Showing 1 to 10 of 46 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Alopecia	127.80	13.07	267	28459	231088	79484574
Fatigue	121.76	13.07	656	28070	929071	78786591
Toxicity to various agents	107.23	13.07	13	28713	421527	79294135
Presbyacusis	81.25	13.07	32	28694	2628	79713034
Pleural thickening	77.70	13.07	32	28694	2950	79712712
Acute kidney injury	72.78	13.07	49	28677	519355	79196307
Blood magnesium increased	72.71	13.07	32	28694	3474	79712188
Appendicolith	68.24	13.07	41	28685	8510	79707152
Pleural fibrosis	67.42	13.07	32	28694	4135	79711527
Product dose omission issue	65.45	13.07	217	28509	247320	79468342

Showing 1 to 10 of 130 entries

Previous1 2 3 4 5…13Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	A11HA05	ALIMENTARY TRACT AND METABOLISM VITAMINS OTHER PLAIN VITAMIN PREPARATIONS Other plain vitamin preparations
CHEBI has role	CHEBI:23354	coenzymes
CHEBI has role	CHEBI:23357	cofactor
CHEBI has role	CHEBI:26348	prosthetic groups
CHEBI has role	CHEBI:50733	Dietary Supplement
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:75772	S. cerevisiae metabolites
CHEBI has role	CHEBI:76971	Escherichia coli metabolites
CHEBI has role	CHEBI:77746	Homo sapiens metabolite
CHEBI has role	CHEBI:78675	fundamental metabolites

Showing 1 to 10 of 13 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Biotin deficiency disease	indication	49607006
Biotinidase deficiency	off-label use	8808004	DOID:856
Propionic acidemia	off-label use	69080001	DOID:14701
Holocarboxylase synthase deficiency	off-label use	360369003	DOID:859
Constipation	contraindication	14760008	DOID:2089
Sarcoidosis	contraindication	31541009	DOID:11335
Dehydration	contraindication	34095006
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Kidney disease	contraindication	90708001	DOID:557

Showing 1 to 10 of 12 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.79	acidic
pKa2	13.37	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Insulin-degrading enzyme	Enzyme	P14735	IDE_HUMAN		EC50	5.60		CHEMBL

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
BTN	PDB_CHEM_ID
001035	NDDF
11819	MMSL
118935	MMSL
118941	MMSL
1203	INN_ID
13813003	SNOMEDCT_US
1588	RXNORM
171548	PUBCHEM_CID
4017638	VUID

Showing 1 to 10 of 24 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
BACMIN	HUMAN PRESCRIPTION DRUG LABEL	19	0682-3001	TABLET, COATED	150 ug	ORAL	UNAPPROVED DRUG OTHER	10 sections
Bonogen Activatorhair loss treatment	HUMAN OTC DRUG LABEL	1	50653-3001	LIQUID	0.00 mL	TOPICAL	unapproved drug other	6 sections
Bonogen Plushair care shampoo	HUMAN OTC DRUG LABEL	4	50653-2001	SHAMPOO	0.06 g	TOPICAL	unapproved drug other	4 sections
Bonogenhair care shampoo	HUMAN OTC DRUG LABEL	4	50653-1001	SHAMPOO	0.06 g	TOPICAL	unapproved drug other	4 sections
Born Hair	HUMAN OTC DRUG LABEL	4	50653-4001	SHAMPOO	0.06 g	TOPICAL	unapproved drug other	7 sections
Concept DHA	HUMAN PRESCRIPTION DRUG LABEL	15	52747-621	CAPSULE, LIQUID FILLED	300 ug	ORAL	unapproved drug other	7 sections
Concept DHA	HUMAN PRESCRIPTION DRUG LABEL	15	52747-621	CAPSULE, LIQUID FILLED	300 ug	ORAL	unapproved drug other	7 sections
Concept OB	HUMAN PRESCRIPTION DRUG LABEL	15	52747-620	CAPSULE	300 ug	ORAL	unapproved drug other	13 sections
Concept OB	HUMAN PRESCRIPTION DRUG LABEL	15	52747-620	CAPSULE	300 ug	ORAL	unapproved drug other	13 sections
Dialyvite	HUMAN PRESCRIPTION DRUG LABEL	9	10542-010	TABLET, COATED	300 ug	ORAL	Unapproved drug other	7 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next